The group's main line of research is serious bacterial infectious diseases, focusing research on the integrated application of omics scienc (wholeomics) in the understanding of disease, under the general assumption that there is an individual genetic basis in the Susceptibility to bacterial infections in general, and meningococcal disease in particular. This approach is also being applied to other life-threatening bacterial diseases, such as pneumococcal, streptococcal, staphylococcal and salmonella infections, among others.
Research in this line is carried out in collaboration with other centers and consortia that we coordinate, mainly through the network ESIGEM (National network of research on meningococcal disease - www.esigem.org) and through the international consortium EUCLIDS (European Childhood Life- Threatening Infectious Diseases Study: www.euclids-project.eu). Both lines financed by ISCIII (FIS- and FP7 Framework Program).
GENVIP has an international competitive vaccine clinical trial unit, which centralizes a significant proportion of the phase 1 to 3 pediatric vaccine trials in Spain and Europe, with vaccine candidates against meningococcus, pneumococcus, human papillomavirus, influenza, or Respiratory syncytial virus. In addition, it collaborates with different promoters in the design of clinical development programs of different vaccine candidates, including TPP, CDP and PIP. Collaborates with the University of Zaragoza and Biofabri in the MTBVAC project. Through this Unit, it will coordinate the pediatric part of the new European mega-project PREPARE (FP7 2013-2019), for the development of the scientific fabric in the case of an emerging or re-emergent pandemic in Europe.
On the other hand, GENVIP works actively applying its concept of wholeomics research to vaccines, seeking to better understand the individual's response to different vaccine antigens, discover new markers of protection and establish individualized strategies of protection through vaccination. In this line they work in close collaboration, among others, with the vaccination group of the University of Oxford (Prof. A. Pollard) and the University of Tampere (Prof. T. Vesikari), among others.
One child dies every 50 seconds as a result of rotavirus infection. There are now available vaccines capable of preventing the disease, and our group has worked on the field analyzes for its implementation and develops protocols for the evaluation of the impact and effectiveness in our environment.
In addition, we now know that repeated exposure to the rotavirus virus, either naturally or through successive doses of vaccines, generates protection. However, the mechanisms involved are practically unknown. Anti-rotavirus serum IgA antibody is known as the best biomarker of protection but it is not well correlated with the clinical protection ant its determination is not a routinary technique. That is why we have developed a specific line with a "wholeomics" approach to evaluate the response to rotavirus, both by natural infection (immunogenomic) and by vaccination (vaccunomic), to understand the immunity of this disease and to identify new biomarkers of protection.
Acute bronchiolitis and in particular the role of heliox as a treatment of these patients, with or without positive pressure, constitute a very fruitful line of work that has led to numerous clinical impact publications. The results of our work today make heliox part of the clinical guidelines for the management of acute bronchiolitis. We are also part of several committees and groups of experts in this pathology, and we are international referents of the use of heliox in the pediatric patient.
We study respiratory infections in childhood, with special attention to respiratory syncytial virus and influenza virus, with special attention to viral co-infection and virus-bacteria interaction.
We apply the "ómico" approach, fundamentally genomic and transcriptomic, to respiratory infections produced by virus, trying to evaluate the susceptibility and clinical evolution of infections by respiratory virus, depending on genetic factors of the host.
In the same line we evaluate the influence of vitamin D, genotypic and phenotypically, on the incidence and evolution of respiratory disease. We also work on the application of new diagnostic methodologies in infection and viral co-infection, as well as the search for new biomarkers. This line has been financed through FIS-ERDF funds and agreements with industry.
We developed this line in collaboration with the network we coordinate (GENDRES - www.gendres.org), Imperial College of London (Dr. J. Herber), Micropathology (Dr. C. Fink), Genomic Institute of Singapore (M.Hibberd / S. Dávila), Oxford Gene Technology (J. Clough) and Nationwide Children's Hospital of Ohio (O. Ramilo / A Mejias), among others. GENVIP is also part of ReSVINET (www.resvinet.org)
GENVIP develops multiple projects in the field of population genetics and various biomedical applications. The purpose is the understanding of the human genetic variability and the consequences that can be derived on the biomedical projects of the group. Specifically, the group works on several lines related to the study of human variability in populations of various continental groups, simulation studies for the analysis of ancestry and its biomedical applications, population stratification and its consequences in case-control studies , Statistical power, and epistasis. The group works closely with the group of Prof. Angel Carracedo, director of the Galician Foundation of Genomic Medicine in Santiago de Compostela and with the National Center of Genotyping also located in the Clinical Hospital of Santiago. Throughout these years, and as a result of these collaborations, a substantial number of genetic publications of the group have emerged in the field of genomics, and we currently have an important series of projects in the field of genomics applied to the study of genomics. Infectious diseases in pediatric age.